Cargando…

MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAF(V600E) Mutation Detected in Circulating-Free DNA

The BRAF(V600E) mutation is associated with melanoma development and its detection in circulating-free DNA cannot be observed in all melanoma patients harboring this mutation in tumor specimens. Beside the circulating-free DNA BRAF(V600E) mutation, other markers of therapeutic response should be ide...

Descripción completa

Detalles Bibliográficos
Autores principales: Salemi, Rossella, Falzone, Luca, Madonna, Gabriele, Polesel, Jerry, Cinà, Diana, Mallardo, Domenico, Ascierto, Paolo A., Libra, Massimo, Candido, Saverio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102751/
https://www.ncbi.nlm.nih.gov/pubmed/30154717
http://dx.doi.org/10.3389/fphar.2018.00856
_version_ 1783349231682060288
author Salemi, Rossella
Falzone, Luca
Madonna, Gabriele
Polesel, Jerry
Cinà, Diana
Mallardo, Domenico
Ascierto, Paolo A.
Libra, Massimo
Candido, Saverio
author_facet Salemi, Rossella
Falzone, Luca
Madonna, Gabriele
Polesel, Jerry
Cinà, Diana
Mallardo, Domenico
Ascierto, Paolo A.
Libra, Massimo
Candido, Saverio
author_sort Salemi, Rossella
collection PubMed
description The BRAF(V600E) mutation is associated with melanoma development and its detection in circulating-free DNA cannot be observed in all melanoma patients harboring this mutation in tumor specimens. Beside the circulating-free DNA BRAF(V600E) mutation, other markers of therapeutic response should be identified. Matrix metalloproteinase-9 (MMP-9) could be one of them as its role as indicator of invasiveness in melanoma have been explored. In this study, MMP-9 was evaluated in melanoma cells after treatment with dabrafenib. In vitro data were validated in 26 melanoma patients, of which 14 treated with BRAF inhibitor alone and 12 treated with both BRAF and MEK inhibitors, by ELISA assay and droplet digital PCR for measuring MMP-9 serum levels and circulating-free DNA BRAF(V600E) mutation, respectively. Statistical analyses were performed to evaluate the prognostic significance of MMP-9, progression-free survival (PFS) and overall survival (OS) according to the BRAF(V600E) mutation and MMP-9 levels. The performed analyses showed that MMP-9 and pEKR1-2 were statistically down-regulated in melanoma cells after treatment with dabrafenib. Circulating-free DNA BRAF(V600E) mutation was detected in 11 out of 26 melanoma patients showing higher levels of MMP-9 compared to those with undetectable BRAF(V600E) mutation. Furthermore, higher levels of MMP-9 and circulating-free DNA BRAF(V600E) mutation were associated with lower PFS and OS. Finally, the monitoring of therapy showed that MMP-9 significantly decreased at T1 and T2, but not at T-last, for the patients with detectable circulating-free DNA BRAF(V600E) mutation. In conclusion, high levels of MMP-9 and circulating-free DNA BRAF(V600E) mutation are associated with poor PFS and OS. MMP-9 may represent a promising indicator of response to BRAF inhibitors in combination with the detection of BRAF(V600E) mutation.
format Online
Article
Text
id pubmed-6102751
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-61027512018-08-28 MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAF(V600E) Mutation Detected in Circulating-Free DNA Salemi, Rossella Falzone, Luca Madonna, Gabriele Polesel, Jerry Cinà, Diana Mallardo, Domenico Ascierto, Paolo A. Libra, Massimo Candido, Saverio Front Pharmacol Pharmacology The BRAF(V600E) mutation is associated with melanoma development and its detection in circulating-free DNA cannot be observed in all melanoma patients harboring this mutation in tumor specimens. Beside the circulating-free DNA BRAF(V600E) mutation, other markers of therapeutic response should be identified. Matrix metalloproteinase-9 (MMP-9) could be one of them as its role as indicator of invasiveness in melanoma have been explored. In this study, MMP-9 was evaluated in melanoma cells after treatment with dabrafenib. In vitro data were validated in 26 melanoma patients, of which 14 treated with BRAF inhibitor alone and 12 treated with both BRAF and MEK inhibitors, by ELISA assay and droplet digital PCR for measuring MMP-9 serum levels and circulating-free DNA BRAF(V600E) mutation, respectively. Statistical analyses were performed to evaluate the prognostic significance of MMP-9, progression-free survival (PFS) and overall survival (OS) according to the BRAF(V600E) mutation and MMP-9 levels. The performed analyses showed that MMP-9 and pEKR1-2 were statistically down-regulated in melanoma cells after treatment with dabrafenib. Circulating-free DNA BRAF(V600E) mutation was detected in 11 out of 26 melanoma patients showing higher levels of MMP-9 compared to those with undetectable BRAF(V600E) mutation. Furthermore, higher levels of MMP-9 and circulating-free DNA BRAF(V600E) mutation were associated with lower PFS and OS. Finally, the monitoring of therapy showed that MMP-9 significantly decreased at T1 and T2, but not at T-last, for the patients with detectable circulating-free DNA BRAF(V600E) mutation. In conclusion, high levels of MMP-9 and circulating-free DNA BRAF(V600E) mutation are associated with poor PFS and OS. MMP-9 may represent a promising indicator of response to BRAF inhibitors in combination with the detection of BRAF(V600E) mutation. Frontiers Media S.A. 2018-08-14 /pmc/articles/PMC6102751/ /pubmed/30154717 http://dx.doi.org/10.3389/fphar.2018.00856 Text en Copyright © 2018 Salemi, Falzone, Madonna, Polesel, Cinà, Mallardo, Ascierto, Libra and Candido. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Salemi, Rossella
Falzone, Luca
Madonna, Gabriele
Polesel, Jerry
Cinà, Diana
Mallardo, Domenico
Ascierto, Paolo A.
Libra, Massimo
Candido, Saverio
MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAF(V600E) Mutation Detected in Circulating-Free DNA
title MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAF(V600E) Mutation Detected in Circulating-Free DNA
title_full MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAF(V600E) Mutation Detected in Circulating-Free DNA
title_fullStr MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAF(V600E) Mutation Detected in Circulating-Free DNA
title_full_unstemmed MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAF(V600E) Mutation Detected in Circulating-Free DNA
title_short MMP-9 as a Candidate Marker of Response to BRAF Inhibitors in Melanoma Patients With BRAF(V600E) Mutation Detected in Circulating-Free DNA
title_sort mmp-9 as a candidate marker of response to braf inhibitors in melanoma patients with braf(v600e) mutation detected in circulating-free dna
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6102751/
https://www.ncbi.nlm.nih.gov/pubmed/30154717
http://dx.doi.org/10.3389/fphar.2018.00856
work_keys_str_mv AT salemirossella mmp9asacandidatemarkerofresponsetobrafinhibitorsinmelanomapatientswithbrafv600emutationdetectedincirculatingfreedna
AT falzoneluca mmp9asacandidatemarkerofresponsetobrafinhibitorsinmelanomapatientswithbrafv600emutationdetectedincirculatingfreedna
AT madonnagabriele mmp9asacandidatemarkerofresponsetobrafinhibitorsinmelanomapatientswithbrafv600emutationdetectedincirculatingfreedna
AT poleseljerry mmp9asacandidatemarkerofresponsetobrafinhibitorsinmelanomapatientswithbrafv600emutationdetectedincirculatingfreedna
AT cinadiana mmp9asacandidatemarkerofresponsetobrafinhibitorsinmelanomapatientswithbrafv600emutationdetectedincirculatingfreedna
AT mallardodomenico mmp9asacandidatemarkerofresponsetobrafinhibitorsinmelanomapatientswithbrafv600emutationdetectedincirculatingfreedna
AT asciertopaoloa mmp9asacandidatemarkerofresponsetobrafinhibitorsinmelanomapatientswithbrafv600emutationdetectedincirculatingfreedna
AT libramassimo mmp9asacandidatemarkerofresponsetobrafinhibitorsinmelanomapatientswithbrafv600emutationdetectedincirculatingfreedna
AT candidosaverio mmp9asacandidatemarkerofresponsetobrafinhibitorsinmelanomapatientswithbrafv600emutationdetectedincirculatingfreedna